CD19 and neoplasm: As a result, HPL-cultured CAR T cells showed potent in vivo anti-tumor activity in both hematological (B cell leukemia treated with CD19 CAR) and solid tumor (pancreatic adenocarcinoma treated with PSCA CAR) models with prolonged T cell persistence.